
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd demonstrates a positive financial outlook due to promising developments in their study that may enable Glioblastoma patients to start treatment 2-3 months earlier, potentially increasing revenue per patient by 20-30%. The company is expected to see accelerated growth in active patients, particularly in the United States and Germany, serving as key indicators for future revenue growth through 2026. Additionally, the anticipated incremental revenue from new markets over the next 12-18 months will further support the company's overall revenue and growth trajectory.
Bears say
NovoCure Ltd is projected to experience a significant decline in EBITDA as revenue growth is expected to take time to materialize, possibly delaying the financial recovery. Analysts estimate that the company may not reach breakeven levels for EBITDA until 2027, potentially indicating challenges in achieving profitability in the near term. This extended timeline for financial improvement raises concerns regarding the sustainability of the company's operations and its overall financial health.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares